Treatment Resistant Bipolar Depression - Full Text View

Sponsor:	Queen's University
Information provided by:	Queen's University
ClinicalTrials.gov Identifier:	NCT00272025

Purpose

To determine if adding Escitalopram to current mood stabilizer (MS) or atypical antipsychotic (AA) will improve in rates similar to or better than adding a placebo (inactive pill)in resistant bipolar patients.

Condition	Intervention	Phase
Bipolar Depression	Drug: Escitalopram Drug: placebo	Phase I

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Efficacy Study
Official Title:	Six Week Double Blind, Randomized Trial of Escitalopram Add On for Treatment Resistant Bipolar Depression

Resource links provided by NLM:

MedlinePlus related topics: Depression

Drug Information available for: Benzetimide Dexetimide Citalopram hydrobromide Citalopram Escitalopram Escitalopram oxalate

U.S. FDA Resources

Further study details as provided by Queen's University:

Primary Outcome Measures:

To evaluate the response rates when Escitalopram vs. placeboes added to the current mood stabilizer or antipsychotic medication [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

To evaluate efficacy, safety and tolerability of added Escitalopram, to a mood stabilizer or atypical antipsychotic. [ Time Frame: 6 weeks ] [ Designated as safety issue: Yes ]

Enrollment:	1
Study Start Date:	October 2006
Estimated Study Completion Date:	January 2010
Estimated Primary Completion Date:	January 2010 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
1: Active Comparator There is a 50% chance of being randomized to Escitalopram in addition to current atypical antipsychotic (minimum dose risperidone 3mg, olanzapine 10mg or seroquel 400mg) or mood stabilizer (lithium, epival or lamotrigine)	Drug: Escitalopram 10mg to 20mg tablet daily for 6 weeks
2: Placebo Comparator	Drug: placebo

Eligibility

Ages Eligible for Study:	18 Years to 65 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Age 18 or older
Diagnosis of Bipolar Disorder and currently be in depressive state, and not responded to mood stabilizer or atypical antipsychotic alone or combined with an antidepressant medication.

Exclusion Criteria:

Pregnant or breastfeeding
History of seizure disorder or other unstable medical condition
Received Electroconvulsive Therapy or Transcranial Magnetic Stimulation in the last three months
Experienced hallucinations or delusions

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00272025

Locations

Canada, Ontario
Providence Care, Mental Health Services
Kingston, Ontario, Canada, K7L 4X3

Sponsors and Collaborators

Queen's University

Investigators

Principal Investigator:

Roumen V. Milev, MD

Queen's University

More Information

No publications provided

Responsible Party:	Providence Care, Mental Health Services ( Roumen, Milev )
Study ID Numbers:	PSIY-207-05
Study First Received:	January 3, 2006
Last Updated:	September 23, 2009
ClinicalTrials.gov Identifier:	NCT00272025 History of Changes
Health Authority:	Canada: Health Canada

Keywords provided by Queen's University:

Bipolar Depression
Escitalopram
Mood Stabilizer
Atypical Antipsychotic

Additional relevant MeSH terms:

Parasympatholytics
Neurotransmitter Uptake Inhibitors
Neurotransmitter Agents
Cholinergic Antagonists
Molecular Mechanisms of Pharmacological Action
Anti-Dyskinesia Agents
Physiological Effects of Drugs
Psychotropic Drugs
Antiparkinson Agents
Cholinergic Agents
Affective Disorders, Psychotic
Mental Disorders
Therapeutic Uses
Dexetimide
Antidepressive Agents, Second-Generation

Antidepressive Agents
Depression
Bipolar Disorder
Depressive Disorder
Serotonin Uptake Inhibitors
Citalopram
Pharmacologic Actions
Behavioral Symptoms
Muscarinic Antagonists
Serotonin Agents
Autonomic Agents
Mood Disorders
Peripheral Nervous System Agents
Central Nervous System Agents

ClinicalTrials.gov processed this record on November 25, 2009